MSLN: Mesothelin
Membrane-anchored forms may play a role in cellular adhesion.
- Drugs that act on it: 5
- Approved: 0
- In phases 1 to 3: 5
- Sponsors: 4
Who is on it, and how far along
Every drug ChEMBL records acting on MSLN, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
- Antibody-drug conjugate 1
- Other 3
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Bayer120%
- Insys Therapeutics120%
- Morphotek120%
- Roche120%
| Anetumab ravtansine | Phase 2 | Bayer | Antibody-drug conjugate | Binding agent | 3 |
| Amatuximab | Phase 2 | Morphotek | Antibody | InhibitorMesothelin inhibitor | 0 |
| LMB-100 | Phase 2 | Roche | Other | Binding agent | 0 |
| RG-7600 | Phase 1 | — | Other | Binding agent | 0 |
| SS1(DSFV)-PE38 | Phase 1 | Insys Therapeutics | Other | Binding agent | 0 |
| Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | Anetumab ravtansine | Phase 1 | Active, not recruiting | National Cancer Institute (NCI) | Jan 25, 2019 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Anetumab ravtansine | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Jul 16, 2018 |
| Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | Anetumab ravtansine | Phase 1 / Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Apr 24, 2017 |
- Mesothelioma0.14
- Neoplasm0.14
- Ovarian cancer0.14
- Malignant pleural mesothelioma0.13
- Pancreatic neoplasm0.13
- Pancreatic ductal adenocarcinoma0.13
- Ovarian carcinoma0.12
- Non-small cell lung carcinoma0.12
- Lung adenocarcinoma0.11
- Triple-negative breast carcinoma0.11
- Familial pancreatic carcinoma0.11
- Colorectal carcinoma0.11
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712878, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q13421, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets